VOR completes Phase 3 UPSTREAM MG enrollment, expands telitacicept to ocular MG
VOR says it completed enrollment in its global Phase 3 UPSTREAM MG trial and expanded its telitacicept global franchise into ocular myasthenia gravis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.